JP Morgan Maintains Overweight on Olema Pharmaceuticals, Raises Price Target to $19
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Anupam Rama maintains an Overweight rating on Olema Pharmaceuticals (NASDAQ:OLMA) and raises the price target from $16 to $19.
September 15, 2023 | 2:16 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JP Morgan maintains an Overweight rating on Olema Pharmaceuticals and raises the price target from $16 to $19, indicating a positive outlook for the company.
The raised price target by JP Morgan indicates a positive outlook for Olema Pharmaceuticals. This could lead to increased investor confidence and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100